William Blair initiates coverage on Savient Pharmaceuticals (SVNT) and Ardea Biosciences (RDEA),...

|About: Savient Pharmaceuticals, Inc. (SVNTQ)|By:, SA News Editor

William Blair initiates coverage on Savient Pharmaceuticals (SVNT) and Ardea Biosciences (RDEA), citing their roles in developing therapies for gout. The firm estimates the U.S. gout market at $2B-$3B; SVNT's Krystexxa will start to gain traction this year, and RDEA's lesinurad, currently in Phase III studies with data expected in 2013, eventually will hit $1.7B in worldwide sales.